author-photo

Serafino Pantano

Novartis

8

Papers

1367

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (289)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

2017 The Lancet
Show All
- Source
- Cite
- Save
Citations (572)
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys Pathomechanistic Role of Peripheral Sympathetic System and Neuropeptide Y

2014 Toxicologic Pathology
Show All
- Source
- Cite
- Save
Citations (19)
Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury

2010 Nature Biotechnology
Show All
- Source
- Cite
- Save
Citations (268)